Alpha Teknova, Inc. (NASDAQ:TKNO) – Equities research analysts at William Blair issued their Q2 2021 earnings per share (EPS) estimates for shares of Alpha Teknova in a research note issued on Tuesday, July 20th. William Blair analyst M. Larew anticipates that the company will post earnings per share of ($0.09) for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Alpha Teknova’s Q3 2021 earnings at ($0.12) EPS, Q4 2021 earnings at ($0.14) EPS, FY2021 earnings at ($0.42) EPS, Q1 2022 earnings at ($0.10) EPS, Q2 2022 earnings at ($0.09) EPS, Q3 2022 earnings at ($0.09) EPS, Q4 2022 earnings at ($0.08) EPS, FY2022 earnings at ($0.36) EPS and FY2023 earnings at ($0.22) EPS.
Several other brokerages also recently weighed in on TKNO. BTIG Research started coverage on Alpha Teknova in a research report on Tuesday. They set a “buy” rating and a $26.00 price target on the stock. Cowen initiated coverage on Alpha Teknova in a report on Tuesday. They set an “outperform” rating on the stock. Finally, Stephens initiated coverage on Alpha Teknova in a research report on Tuesday. They set an “overweight” rating and a $27.00 price target for the company.
Alpha Teknova Company Profile
Alpha Teknova, Inc provides reagents for bioprocessing, bioproduction, and molecular diagnostics. The company's reagents enable the discovery, research, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. It offers liquid culture, dry culture, agar, and animal-free media, as well as pre-poured plates, biological buffers, solutions, chemicals, and various treated and certified waters.
Recommended Story: Are sell-side analysts objective?
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.